TACSTD2 and cancer: The high expression of Trop-2 in TNBC cells makes it a suitable candidate for targeted therapies, such as ADCs like sacituzumab govitecan (SG), which exploit Trop-2 as a specific binding site to deliver cytotoxic agents directly to cancer cells [52].